Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Combination of anti-PD-1 antibodies and bispecific anti-CD20/anti-CD3 antibodies to treat cancer

Combination of anti-PD-1 antibodies and bispecific anti-CD20/anti-CD3 antibodies to treat cancer

US Patent 12054557 · Granted Aug 6, 2024

Estimated economic value: $61,228,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Intralesional administration of PD-1 inhibitors for treating skin cancer2025
Non-human animals expressing humanized CD3 complex2025
Mouse having a humanized cluster of differentiation 47 gene2025
Combination therapy to treat brain cancer2025
Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD2025
Multispecific antigen-binding molecules and uses thereof2025
Non-human animals having a humanized signal-regulatory protein gene2024
Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use ther2024
Anti-CD8 antibodies and uses thereof2024
Methods of treating skin cancer with Carboxypeptidase Vitellogenic Like (CPVL) i2024
Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging2024
Anti-CTLA-4 antibodies and uses thereof2024